Dr Kyra Ungerleider earned her Bachelor of Science in Neuroscience from The Ohio State University before being awarded a Cancer Research Training Award Fellowship at the National Institutes of Health (NIH). During her tenure at the NIH, she investigated cellular mechanisms relevant to aging and aging-related diseases while gaining experience in high-throughput drug screening strategies. She subsequently completed her PhD in Clinical Neuroscience at the University of Cambridge, where she developed expertise in high-throughput CRISPR-Cas9 screening technologies and advanced molecular biology techniques. Dr. Ungerleider’s scientific excellence has been recognized with several notable awards, including the Federal Technology Transfer Award from the NIH, the Cambridge Reproductive Development Fund Award, and Clare Hall Boak Research Scholarship. 

At OvartiX, Kyra is leading the development of high-throughput screening capabilities to accelerate our drug discovery efforts in female reproductive health.